• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Recursion Pharmaceuticals Stock Is Up 6.6% And What's Next

    Simply Wall St·10/28/2026 03:16:15
    Listen to the news
    • Recursion Pharmaceuticals reported that Sanofi has optioned the first development candidate from their AI-driven collaboration, triggering a US$10 million milestone and shifting this asset fully into Sanofi’s pipeline. Recursion remains eligible for more than US$300 million in future milestones and double digit royalties if approved.
    • The follow-on equity raise of about US$200 million, combined with progress on REC-4881 in FAP and REC-1245 in oncology, directly ties Recursion’s capital position to its AI-enabled pipeline execution.
    • We will look at how Recursion Pharmaceuticals’ investment narrative is affected by Sanofi’s option decision and recent AI-driven clinical progress.

    Extend your research beyond Recursion Pharmaceuticals and scan a hand-picked 34 healthcare AI stocks that are also tying AI platforms directly to real drug programs and fresh funding events.

    Recursion Pharmaceuticals Investment Narrative Recap

    Owning Recursion Pharmaceuticals means believing its AI drug discovery platform can consistently turn data into real medicines and partnerships. The most important near term catalyst is operational, not financial. It lies in how cleanly REC-4881 and REC-1245 progress through upcoming data events and how those readouts influence partner interest. The Sanofi option decision validates one program but does not remove pipeline and execution risk.

    The biggest current risk is still the combination of cash burn, equity dilution and dependence on partner milestones to support a long R&D runway. The recent US$200 million follow on offering extends funding, yet also underlines how sensitive the story remains to capital markets and collaboration momentum.

    The Sanofi option on the immunology candidate is the most relevant update for this news. It shifts a discovery asset fully into a partner funded pipeline, sends a US$10 million milestone into Recursion’s income line and converts future economics from cost center to potential profit stream if further milestones and royalties are achieved.

    For catalysts, that handoff matters because it frees Recursion’s internal resources to lean harder into REC-4881 and REC-1245 while still keeping exposure to partnered upside. The risk side is that success now depends on Sanofi’s development pace and priorities, which adds another layer of uncertainty on timing for future payments and validation.

    Recursion Pharmaceuticals’ current analyst framework points to forecast revenue of US$116.3 million and projected earnings of US$18.7 million by 2029, built on assumed yearly revenue growth of 28.5% and an earnings shift of roughly US$537.6 million from a loss of US$518.9 million today to the forecast profit level.

    Uncover how Recursion Pharmaceuticals' fair value indicates an 81% potential upside to its current price, which could narrow quickly if sentiment catches up.

    NasdaqGS:RXRX 1-Year Stock Price Chart
    NasdaqGS:RXRX 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view puts the equity dilution risk front and center for Recursion Pharmaceuticals. Before this news, the most optimistic analysts were already modeling revenue of about US$382.1 million and earnings of roughly US$65.7 million by 2029, far above consensus. That is a much richer narrative. These forecasts and the new Sanofi milestone may eventually be revised, so treat them as moving parts and compare several viewpoints before making your own call.

    Explore 6 other Recursion Pharmaceuticals fair value estimates, including one that suggests as much as 147% above the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Ideas Beyond Recursion Pharmaceuticals?

    Once you have formed a view on Recursion Pharmaceuticals, it often helps to widen the lens and compare it with other opportunities that fit clear, disciplined filters. The Simply Wall St Screener can help you quickly surface a shortlist that matches your own risk tolerance and return goals.

    • For investors who want potential upside without stretching into weaker businesses, review a curated 29 high quality undervalued stocks that combine quality fundamentals with prices that analysts judge as attractive relative to those basics.
    • If capital preservation sits high on your priority list, look through a 30 resilient stocks with low risk scores that score well on financial strength and business stability so you can focus research time on sturdier candidates.
    • When you want something off the beaten path, scan a 21 high quality undiscovered gems that pair strong fundamentals with relatively low market attention.